Molecular Vision 2012; 18:2882-2895 <>
Received 29 June 2012 | Accepted 29 November 2012 | Published 01 December 2012

The D1 dopamine receptor agonist, SKF83959, attenuates hydrogen peroxide-induced injury in RGC-5 cells involving the extracellular signal-regulated kinase/p38 pathways

Guang-Yu Li,1 Ting Li,2 Bin Fan,1 Yong-Chen Zheng,2 Tong-Hui Ma2

1Department of Ophthalmology, Second Hospital of JiLin University, Changchun, China; 2State Key Laboratory, Second Hospital of JiLin University, Changchun, China

Correspondence to: Tong-Hui Ma, Second Hospital of JiLin University, ChangChun, 130041, China; Phone: +86-431-89575858; FAX: +86-431-89575858 email:


Purpose: Oxidative stress is widely implicated in the death of retinal ganglion cells associated with various optic neuropathies. Agonists of the dopamine D1 receptor have recently been found to be potentially neuroprotective against oxidative stress–induced injury. The goal of this study was to investigate whether SKF83959, a next-generation high-affinity D1 receptor agonist, could protect retinal ganglion cell 5 (RGC-5) cells from H2O2-induced damage and the molecular mechanism involved.

Methods: We examined expression of the D1 receptor in RGC-5 cells with reverse-transcription–PCR and immunoblotting and assessed neuroprotection using propidium iodide staining and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. In addition, we monitored the activation and involvement of members of mitogen-activated protein kinase family, extracellular signal-regulated kinase (ERK), p38 and c-Jun NH2-terminal kinase, with western blot and specific inhibitors.

Results: We found that the D1 receptor was expressed in RGC-5 cells, but the sequence analysis suggested this cell line is from mouse and not rat origin. SKF83959 exhibited a remarkable neuroprotective effect on H2O2-damaged RGC-5 cells, which was blocked by the specific D1 receptor antagonist, SCH23390. ERK and p38 were activated by SKF83959, and pretreatment with their inhibitors U0126 and SB203580, respectively, significantly blunted the SKF83959-induced cytoprotection. However, the specific c-Jun NH2-terminal kinase inhibitor, SP600125, had no effect on the SKF83959-induced protection.

Conclusions: We conclude that SKF83959 attenuates hydrogen peroxide–induced injury in RGC-5 cells via a mechanism involving activation of the ERK and p38 pathways and the D1 receptor is a potential molecular target for developing neuroprotective drugs.


Oxidative stress is widely implicated in the death of retinal ganglion cells (RGCs) associated with various ocular neurodegenerative disorders, such as glaucoma, Leber hereditary optic neuropathy, ischemic optic neuropathy, and traumatic optic neuropathy [1-4]. Studies have demonstrated that under oxidative stress, reactive oxygen species (ROS) including free radicals such as superoxide (O2−), hydroxyl radical (HO), and hydrogen peroxide (H2O2) are generated at high levels inducing cellular damage and even cell death [5]. Elevated levels of ROS may cause increased permeability of the blood–retina barrier, tubulin alterations, and perturbation in synaptic transmission [6-8]. Emerging evidence further suggests that under pathologic conditions, excessive amounts of ROS induced by oxidative stress can modify proteins, lipids, and DNA to alter their functions and activate signaling pathways resulting in death of retinal neurons [9].

Activation of the dopamine D1 receptor was recently found to be potentially neuroprotective against oxidative-stress damage in retinal neurons including RGCs [10]. Dopamine is the main catecholamine found in the retina of most species, which is synthesized from the L-amino acid tyrosine [11]. Dopamine has been suggested to play a developmental role in the embryonic retina [12]. Based upon structural and pharmacological similarities, the dopamine receptor family includes five members, which are divided into two subfamilies: the D1-like family, comprising D1 and D5 receptors, and the D2-like family, containing D2, D3, and D4 receptors [13]. D1-like receptors have high structural homology across species between amino acids 445 and 488 [14]. In addition, D1-like receptors do not contain introns in their protein coding regions decreasing the possibility of observing receptor variants [15]. The protein structure of D1-like dopamine receptors consists of putative transmembrane domains, potential glycosylation sites in the first extracytoplasmic loop, and a carboxyl terminal tail [16]. Upon stimulation, D1-like receptors trigger signal transduction cascades mediated through adenylyl cyclase or phosphoinositide metabolism accompanied by subsequent enhancement of multiple downstream kinase cascades [15]. In clinical settings, agonists of the D1 receptor have been used in treating Parkinson disease since dihydrexidine (DHX), the first high-affinity D1 agonist with full intrinsic activity, was developed [17]. During Parkinson disease therapy, another important, possible benefit of using D1 receptor agonists was found: neuroprotection [18]. Moreover, many studies show that activation of the D1 receptor also provides excellent ocular neuroprotection [19,20]. Kipnis et al. found that the selective dopamine receptor D1 agonist, SKF38393, a first-generation D1 receptor agonist, protected primary cultures of fetal rat retinal cells from glutamate neurotoxicity [21]. Subsequently, Maher et al extended the protective effects of SKF-38393 by demonstrating its ability to also protect retinal ganglion cells (RGC-5) from oxidative stress-mediated injury induced by either glutamate plus buthionine sulfoximine (BSO), tert-butyl peroxide (t-BOOH), or H2O2 treatments [22].

Members of the mitogen-activated protein kinase (MAPK) family play a critical role in oxidative stress–induced neuronal death since MAPK signaling cascades involve highly conserved serine/threonine kinases connecting cell surface receptors to regulatory targets in response to oxidative stress [23]. The MAPK signaling pathways mainly occur through activation of three kinase subfamilies: the stress-activated protein kinases (c-Jun NH2-terminal kinase [JNK]), the p38 kinases, and the extracellular signal-regulated kinases (ERK) [24]. Activation of MAPKs is through upstream kinases, including mitogen-activated protein kinase kinase 1 and 2 (MKK1/2), MKK3/6, and MKK4/7, which can reversibly phosphorylate threonine and tyrosine residues of the TXY motif in the catalytic domain. ERK and p38 normally are activated by MKK1/2 and MKK3/6, respectively, whereas JNK is activated by MKK4/7 [25]. Once activated, MAPKs phosphorylate several cellular substrates to propagate signaling cascades leading to many forms of cellular responses, including proliferation, differentiation, and death [26]. Although prior studies have explored the molecular basis of neuroprotection offered by D1 receptor agonists in various neuronal cells [27-30], the exact signaling pathway elicited by D1 receptor stimulation of RGCs is still unclear. Whether D1 receptor agonists protect RGCs against oxidative stress–induced injury through regulating MAPK pathways still needs to be elucidated.

The goal of this study was to determine whether SKF83959, a next-generation high-affinity D1 receptor agonist [31], protected RGCs against oxidative stress-dependent damage. To test this hypothesis, the retinal ganglion cell line, RGC-5, was used as an in vitro model to determine the molecular basis of SKF83959 protection. The results indicated that SKF83959 protects RGC-5 cells from H2O2-induced injury in an ERK- and p38-dependent fashion.


Chemicals and reagents

Cell culture media and additives were obtained from Hyclone (Beijing, China), and plastic cultureware was supplied by DingGuo BioTech (Beijing, China). The rabbit anti-D1 receptor, anti-p-ERK, anti-p38, and anti-p-JNK monoclonal antibodies were purchased from Bioworld (Hong Kong, China). The mouse anti-β-actin monoclonal antibody was obtained from Chemicon (Watford, UK). The reverse-transcription–PCR (RT–PCR) commercial kit and DNA marker were purchased from Takara (Dalian, China). The anti-rabbit immunoglobulin G and all the other reagents and inhibitors were purchased from Sigma-Aldrich (Shanghai, China).

Cell culture

RGC-5 cells were ordered from the American Type Culture Collection (ATCC, Manassas, VA) and grown in Dulbecco’s modified Eagle’s medium (DMEM; Hyclone, Beijing, China) supplemented with 10% heat-inactivated fetal bovine serum, 100 U/ml penicillin, and 100 mg/ml streptomycin in a humidified atmosphere of 95% air and 5% CO2 at 37 °C. The doubling time of the cells was approximately 20 h under these conditions, and the cells were generally passaged by trypsinization at a ratio of 1:6 every 3 to 4 days.

Cell viability assays and propidium iodide staining

Cell viability was assessed using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay modified from that described by Mosmann et al. [32]. MTT was added to each well at a final concentration of 0.5 mg/ml in minimum essential medium (MEM) that lacked serum and phenol red and incubated for 1 h at 37 °C. Reduced MTT (blue formazan product) was solubilized with dimethyl sulfoxide, and the absorbance was determined using an automated microplate reader (Titertek Plus MS212; ICN Flow, Thame, UK) with a 570 nm test wavelength and a 690 nm reference wavelength. Concentrations of U0126, SB203580, and SP600125 were preliminarily screened to assess the effects of drug alone toxicity in the cultures to select an appropriate non-toxic concentration (data not shown). For propidium iodide (PI) staining, the cells were first cultured in a 24-well plate for 24 h. After being treated with 500 μM H2O2 for 5 h, the cells were then treated with the PI solution at a final concentration of 2 μg/ml and incubated for 10 min at room temperature. The PI-positive cells were visualized on an inverted fluorescence microscope (Leica; Berlin, Germany).

RNA extraction and real-time polymerase chain reaction amplification

Total RNA was extracted from RGC-5 cells using the TRIzol method (Takara). RNA samples were stored at −80 °C. The RNA concentration was determined spectrophotometrically by measuring absorbance at 260 nm and with agarose gel electrophoresis. RT–PCRs were performed with the RT–PCR commercial kit (Takara), using 1 µg of total RNA treated with DNase. Reactions were incubated at 45 °C for 45 min and 94 °C for 2 min, and then through 30 cycles of 94 °C for 30 s, 55 °C for 1 min, and 72 °C for 30 s, with a final extension incubation of 7 min at 72 °C. Amplification product was analyzed with agarose gel electrophoresis and sequenced from Takara. Analyses and comparisons of the resulting sequence were performed using the BLAST tool (NCBI online).

Western blotting

RGC-5 cells were sonicated in protein lysate buffer (20 mm Tris-HCl, pH 7.4, 25 °C, 2 mm EDTA, 0.5 mm ethyl glycol tetraacetic acid [EGTA], 1 mm dithiothreitol, 50 mg/ml leupeptin, 50 mg/ml pepstatin A, 50 mg/ml aprotinin, and 0.1 mm phenylmethylsulfonyl fluoride). The bicinchoninic acid assay (BCA) method was used to estimate protein concentrations [33]. An equal amount (20 µg) of cell lysate was dissolved in sample buffer (62.5 mm Tris-HCl, pH 7.4, 4% sodium dodecyl sulfate, 10% glycerol, 10% β-mercaptoethanol, and 0.002% bromophenol blue), and the samples were boiled for 3 min. Electrophoresis was performed as previously reported [34] using 10% polyacrylamide gels containing 0.1% sodium dodecyl sulfate. Proteins were transferred to nitrocellulose membranes, and the blots were incubated for 3 h at room temperature with primary antibodies (1:1000). The blots were then incubated with the appropriate biotinylated secondary antibodies. Reactivity was detected using the ECL (Pierce, Rockford, IL) detection system, following the manufacturer's protocol.

Statistical analysis

Each experiment was repeated at least twice. Data are expressed as mean±standard error of the mean (SEM). Differences between means were evaluated using one-way analysis of variance (ANOVA) followed by the Bonferroni test. The accepted level of significance in all cases was p<0.001.


The dopamine D1 receptor was expressed in RGC-5 cells

Before investigating the neuroprotective action of SKF83959, the specific agonist of the D1 receptor, we first confirmed whether the D1 receptor was expressed in RGC-5 cells at the mRNA and protein levels by using RT–PCR and immunoblotting. As shown in Figure 1A, after total mRNA from RGC-5 cells was isolated and reverse transcribed into cDNA, the target sequence of about 215 bp from the D1 receptor cDNA was amplified with specific primers (upstream primer 5′-ATG CCA TAG AGA CTG TAA GC-3′; downstream primer 5′-GAC TAT GAC ACC GAT GTC TC-3′). The amplicon was analyzed with agarose electrophoresis and finally confirmed with DNA sequencing. Interestingly, subsequent nucleotide alignments using the BLAST server showed that the amplicon was 100% identical to the mouse D1A receptor, but only 91% and 88% homologous to rat and human D1A, respectively (Figure 1C). This indicates that RGC-5 cells were probably derived from mouse and not rat retina as previously reported [35]. Next, we further confirmed D1 receptor expression at the protein level with immunoblotting. As shown in Figure 1B, a specific protein band for the D1 receptor was detected at the appropriate molecular weight of about 50 kDa. In addition, the western blots also showed that treatment with 30 μM SKF83959 did not affect levels of the D1 receptor relative to the internal control, β-actin. Thus, these results suggested that the dopamine D1 receptor was expressed in RGC-5 cells.

SKF83959 protected retinal ganglion cell 5 cells from H2O2-induced damage

As shown in Figure 2A–F, after treatment with 500 μM hydrogen peroxide for 5 h, massive cell loss of viability was positively detected with the PI reagent as red fluorescence observed using inverted fluorescence microscopy, whereas pretreatment with 30 μM SKF83959 30 min before 500 μM H2O2 was added effectively reduced cell death to only a few cells positively stained with PI. Consistent with the PI result, pretreatment with 20–30 μM SKF83959 significantly increased cell viability to 52.7±10.2% (20 μM) and 72.4±16.6% (30 μM) compared to 500 μM H2O2-alone treated cells (31.1±7.5%) as monitored with MTT assay (Figure 2G). Figure 2H showed that the cytoprotection of SKF83959 was remarkably blocked by the application of 50–100 μM SCH23390, a specific antagonist of the D1 receptor, which caused a significant reduction in cell viability back to 42.6±9.4% (50 μM) and 32.3±7.1% (100 μM). These results indicated that SKF83959 protected RGC-5 cells from oxidative stress–induced injury through a D1 receptor–triggered signaling pathway.

SKF83959-induced neuroprotection involved activation of extracellular signal-regulated kinase

To demonstrate the role of ERK in SKF83959-induced neuroprotection, we first monitored any change in its active form, p-ERK, caused by H2O2 treatment. RGC-5 cells were treated with 500 μM H2O2 for various periods (1–5 h) and the active form, p-ERK, and total ERK were determined with western blot. As shown in Figure 3A, treatment with 500 μM H2O2 caused gradual reduction in p-ERK from 1 h to 5 h compared with the control cells. p-ERK consists of two protein isoforms, p-44 and p-42, detected as double bands with western blot. Hydrogen peroxide seemed to have a more dramatic effect on p-44 rather than p-42 since the protein of p-44 was undetectable by 3 h after treatment with 500 μM H2O2, whereas H2O2 treatment had little effect on total ERK. The quantitative analysis demonstrated a significant decrease in p-ERK levels from 1 h to 5 h after treatment with 500 μM H2O2 with no difference in total ERK levels (Figure 3B,C). Next, we monitored the effect of SKF83959 on p-ERK levels to see whether it regulated the activation of ERK. As shown in Figure 4A,B, treatment with 30 μM SKF-83959 30 min before hydrogen peroxide was applied led to remarkable preservation of p-ERK at relatively normal levels. However, preapplication of the specific MEK/ERK inhibitor, 20 μM U0126, attenuated the effect of SKF83959 on the p-ERK levels. To further investigate the role of ERK in SKF83959-induced neuroprotection, we monitored the action of U0126 on cell viability with MTT assay. As shown in Figure 4C, pretreatment with 30 μM SKF83959 increased cell viability by 74.7±10.2% vs. 500 μM H2O2-alone treated cells (30.2±7.5%), whereas preapplication of 20 μM U0126 significantly attenuated the protection, and cell viability was reduced to 48.2±6.3% compared to the SKF83959-pretreated cells. These results indicated that ERK was involved in the SKF83959-induced neuroprotective mechanism in H2O2-injured cells.

Activation of p38 MAPK was involved in neuroprotection induced by SKF83959

Similar to the results for active ERK levels, treatment with 500 μM H2O2 substantially decreased the levels of p-p38 in a time-dependent manner with no effect on total p38 levels as assessed with western blot (Figure 5A). Further quantitative analysis confirmed that p-p38 was significantly reduced from 1 h to 5 h compared to controls (Figure 5B), whereas total p38 levels were largely unaffected from 1 h to 4 h except a slight decrease at 5 h (Figure 5C). Importantly, pretreatment with 30 μM SKF83959 30 min before H2O2 was added largely prevented an H2O2-induced decrease in p-p38 levels (Figure 6A,B), which suggested that SKF83959 also used the p38 pathway for protection in H2O2-treated cells. Application of 200 μM SB203580, a specific inhibitor of p38, blocked the preservation effect of SKF83959 on p-p38 levels (Figure 6A,B). In addition, we assessed the role of p38 in SKF83959-induced cytoprotection with MTT assay. As shown in Figure 6C, preapplication of 200 μM SB203580 significantly blunted the SKF83959-enhanced cell viability against the H2O2 insult (from 70.7±12.8% back to 54.1±8.3%). These results indicated that activation of p38 also contributed to the neuroprotective mechanism induced by SKF83959 treatment of oxidative-stressed cells.

c-Jun NH2-terminal kinase was not associated with SKF83959-induced neuroprotection

We next monitored the third member of MAPK family, JNK, at various time points after treatment with 500 μM H2O2. Different from the two other family members, applying hydrogen peroxide from 1 h to 5 h had little influence on p-JNK or total JNK levels detected with western blot (Figure 7A), and no significant changes were assessed with further statistical analysis (Figure 7B,C). Consistent with this, the specific inhibitor of JNK, 100 μM SP600125, failed to block the 30 μM SKF83959-induced cytoprotection in 500 μM H2O2-treated cells with no significant viability reduction determined with MTT assay compared with 30 μM SKF83959-treated cells (Figure 8A). However, coapplication of the ERK and p38 inhibitors remarkably reversed the cytoprotection effects of SKF83959. As shown in Figure 8B, treatment with 30 μM SKF83959 increased cell viability by 73.5±11.4% compared with the 500 μM H2O2-alone treated cells (34.2±7.6%), whereas copretreatment with 20 μM U0126 and 200 μM SB203580 caused a reduction in cell viability to 34.8±8.1%. This almost completely blocked the 30 μM SKF83959-induced cytoprotection.


The RGC-5 cell line has been widely used in ophthalmic research to study ocular neurodegeneration, neuroprotection, and neuroregeneration mechanisms. We appreciate that the cell line may not behave like primary RGCs in all aspects, and this is a potential limitation of our data set. However, generating primary cultures of RGCs is time-consuming and technically difficult. Therefore, for this initial study our goal was to use the RGC-5 cell line to determine the neuroprotective mechanism stimulated by SKF83959 with the expectation that the conclusions can be extrapolated to and verified in primary RGCs in a future work.

According to the first reference to RGC-5 cells previously published by Krishnamoorthy et al. [35], the RGC-5 cell line was derived from post-natal day 1 rat retinal cells by transforming with the ψ2 E1A virus and expressed thymus cell antigen 1(Thy-1), brain-3C (Brn-3C), Neuritin, the N-methyl D-aspartate (NMDA) receptor, the gamma-aminobutyric acid (GABA-B) receptor, and synaptophysin but did not express glial fibrillary acidic protein (GFAP), syntaxin 1, and 8A1, a neurofilament marker. To confirm whether RGC-5 cells expressed the D1 receptor, we examined the mRNA and protein levels by using RT–PCR and immunoblotting. Our results showed that a specific protein band for the D1 receptor was detected at the appropriate molecular weight of about 50 kDa compared with the positive control. Furthermore, we designed RT–PCR primers according to the mRNA sequence of the D1 receptor and obtained an amplicon with 215 bp. The sequencing results from this amplicon demonstrated that it was the targeted part of the D1 receptor mRNA. However, interestingly, the nucleotide alignment demonstrated that the amplicon had 100% identity with Mus musculus D1 receptor mRNA and 91% identity with Rattus norvegicus. The origin of the RGC-5 cell line has been somewhat controversial. Van Bergen et al. [36] recharacterized RGC-5 cells, and the study showed that the cell line was of mouse (Mus musculus) and not rat (Rattus norvegicus) origin, based on mitochondrial and nuclear DNA analyses [36]. Although not a primary focus of this study, our findings also support the notion that the RGC-5 cell line is of mouse origin. Therefore, the murine nature of the cell line should be considered in future research using RGC-5 cells to allow researchers to better select antibodies, primers, etc.

The dopamine (DA) D1 receptor is the most highly expressed subtype in the DA receptor family. The selective D1 agonist, SKF83959, belongs to the benzazepine family and possesses high affinity and selectivity. SKF83959 has a Ki less than 5 nM and selectivity for the D1 over the D2 receptor that is more than 3,000-fold [13]. We appreciate that the drug is not entirely specific for the D1 receptor but the higher reported affinity for the D1 receptor versus the D2 receptor, and the fact that the effects of the agonist were attenuated by a specific D1 receptor antagonist support our conclusion that the effects observed were related to the D1 receptor. We observed that SKF83959 treatment provided excellent neuroprotection of RGC-5 cells against oxidative stress–induced injury. Pretreatment with 30 μM SKF83959 significantly increased cell viability from 33.8% to 76.2% in hydrogen peroxide–treated cells. The cytoprotection of SKF83959 was blocked by application of 50–100 μM SCH23390, a specific antagonist of the D1 receptor. The retinal ganglion cells might respond to dopamine through two types of dopamine receptors. One is the D1 receptor based on data demonstrating detection with specific monoclonal and polyclonal antibodies. Another is a heterooligomeric D2–D5 receptor, based on calcium influx (spike firing) caused by agonists and the blockade of agonist responses by administration of antagonists. However, how retinal ganglion cells utilize D1 and/or D2–D5 receptors depends on various factors such as the G-proteins recruited, the duration and intensity of intracellular Ca2+ increases, and the subsequent signaling cascades [37].

To further investigate the molecular mechanism of SKF83959-induced neuroprotection in this study, we first assessed changes in phosphorylated, active levels in all three subfamilies of MAPK, ERK, p38, and JNK in response to H2O2-induced oxidative stress in RGC-5 cells. Our results showed that treatment with 500 μM H2O2 led to a gradual decline in p-ERK and p-p38 levels from 1 h to 5 h relative to untreated cells, but no obvious influence on p-JNK. Pretreatment with 30 μM SKF83959 resulted in a remarkable preservation of p-ERK and p-p38 levels and increased cell viability. The application of specific inhibitors of ERK and p38 significantly abrogated the cytoprotection of SKF83959 and attenuated the preservation of p-ERK and p-p38 levels. These results indicated that activation of ERK and p38 plays an important role in the SKF83959-triggered neuroprotective mechanism. ERK1/2 is phosphorylated and activated by mitogen-activated kinase/ERK kinase 1/2 [38]. This activation further leads to phosphorylation of various substrates including the 90 kDa ribosomal S6 protein kinase (Rsk), cytosolic phospholipase A2, and transcription factors such as c-Myc, NF-IL6, Tal-1, Ets-2, and Elk [39]. The upregulation of gene transcription results in increased expression of antiapoptotic Bcl-2 family members and inhibitor of apoptosis proteins (IAPs) [40]. For p38, it is generally phosphorylated and activated by MEK3/6 in response to variety environmental stresses and inflammatory cytokines. Antiapoptotic roles of p38 have been described in endothelial cells exposed to anoxia-reoxygenation [41], differentiating neurons [42], and activated macrophages [43]. The role of p38 in preventing apoptosis is similar to that described for ERK involving regulation of protective transcription factor activity [44]. In our study, another subfamily member of MAPK, JNK, appeared to play a less important role in the molecular mechanism of oxidative stress–induced death and SKF83959-caused cytoprotection in RGC-5 cells since no significant change in active p-JNK levels was found, and its specific inhibitor failed to block SKF-induced neuroprotection. The cells appeared to have basally high levels of phosphorylated, active forms of the kinases in control conditions. One explanation for this phenomenon is that basal activity of the enzymes might be particularly high due to trophic or mitogenic stimuli during the culture conditions.

To our knowledge, this study is the first demonstration that the dopamine D1 receptor is expressed in RGC-5 cells, and its amplicon from mRNA suggests RGC-5 cells are from mouse (Mus musculus) and not rat (Rattus norvegicus) origin, which is consistent with a previous study [36]. The agonist of the D1 receptor, SKF-83959, effectively rescued RGC-5 cells against hydrogen peroxide–induced injury, and ERK and p38 play important roles in the molecular mechanism of neuroprotection. Our results may enhance the current understanding of the molecular mechanisms of retinal ganglion cell death in diseases associated with oxidative stress and provide a basis for future studies to develop neuroprotective drugs with the dopamine D1 receptor as a new therapeutic target.


This work was supported by grants from the Natural Science Foundation of China (No.81100660; No.30801271), the International Joint Project from Science and Technology Bureau of Jilin Province (No.20090746), the Natural Science Foundation from Science and Technology Bureau of Jilin Province (No.201015173) and Basic Science Foundation of JiLin University (2012).


  1. Tezel G. The immune response in glaucoma: a perspective on the roles of oxidative stress. Exp Eye Res. 2011; 93:178-86. [PMID: 20709058]
  2. Johns DR, Colby KA. Treatment of Leber's hereditary optic neuropathy: theory to practice. Semin Ophthalmol. 2002; 17:33-8. [PMID: 15513454]
  3. Goldenberg-Cohen N, Dadon-Bar-El S, Hasanreisoglu M, Avraham-Lubin BC, Dratviman-Storobinsky O, Cohen Y, Weinberger D. Possible neuroprotective effect of brimonidine in a mouse model of ischaemic optic neuropathy. Clin Experiment Ophthalmol. 2009; 37:718-29. [PMID: 19788670]
  4. Levkovitch-Verbin H, Harris-Cerruti C, Groner Y, Wheeler LA, Schwartz M, Yoles E. RGC death in mice after optic nerve crush injury: oxidative stress and neuroprotection. Invest Ophthalmol Vis Sci. 2000; 41:4169-74. [PMID: 11095611]
  5. Burton GJ, Jauniaux E. Oxidative stress. Best Pract Res Clin Obstet Gynaecol. 2011; 25:287-99. [PMID: 21130690]
  6. Li J, Wang JJ, Yu Q, Chen K, Mahadev K, Zhang SX. Inhibition of reactive oxygen species by Lovastatin downregulates vascular endothelial growth factor expression and ameliorates blood-retinal barrier breakdown in db/db mice: role of NADPH oxidase 4. Diabetes. 2010; 59:1528-38. [PMID: 20332345]
  7. Sugimoto K, Yasujima M, Yagihashi S. Role of advanced glycation end products in diabetic neuropathy. Curr Pharm Des. 2008; 14:953-61. [PMID: 18473845]
  8. Bringmann A, Pannicke T, Biedermann B, Francke M, Iandiev I, Grosche J, Wiedemann P, Albrecht J, Reichenbach A. Role of retinal glial cells in neurotransmitter uptake and metabolism. Neurochem Int. 2009; 54:143-60. [PMID: 19114072]
  9. Tezel G. Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences. Prog Retin Eye Res. 2006; 25:490-513. [PMID: 16962364]
  10. Yamauchi T, Kashii S, Yasuyoshi H, Zhang S, Honda Y, Ujihara H, Akaike A. Inhibition of glutamate-induced nitric oxide synthase activation by dopamine in cultured rat retinal neurons. Neurosci Lett. 2003; 347:155-8. [PMID: 12875909]
  11. Reis RA, Ventura AL, Kubrusly RC, de Mello MC, de Mello FG. Dopaminergic signaling in the developing retina. Brain Res Rev. 2007; 54:181-8. [PMID: 17292477]
  12. Kubrusly RC, Guimaraes MZ, Vieira AP, Hokoc JN, Casarini DE, de Mello MC, de Mello FG. L-DOPA supply to the neuro retina activates dopaminergic communication at the early stages of embryonic development. J Neurochem. 2003; 86:45-54. [PMID: 12807423]
  13. Zhang J, Xiong B, Zhen X, Zhang A. Dopamine D1 receptor ligands: where are we now and where are we going. Med Res Rev. 2009; 29:272-94. [PMID: 18642350]
  14. Demchyshyn LL, Sugamori KS, Lee FJ, Hamadanizadeh SA, Niznik HB. The dopamine D1D receptor. Cloning and characterization of three pharmacologically distinct D1-like receptors from Gallus domesticus. J Biol Chem. 1995; 270:4005-12. [PMID: 7876148]
  15. Lachowicz JE, Sibley DR. Molecular characteristics of mammalian dopamine receptors. Pharmacol Toxicol. 1997; 81:105-13. [PMID: 9335067]
  16. Hartman DS, Civelli O. Dopamine receptor diversity: molecular and pharmacological perspectives. Prog Drug Res. 1997; 48:173-94. [PMID: 9204687]
  17. McCorvy JD, Watts VJ, Nichols DE. Comparison of the D₁ dopamine full agonists, dihydrexidine and doxanthrine, in the 6-OHDA rat model of Parkinson's disease. Psychopharmacology (Berl). 2012; 222:81-7. [PMID: 22222862]
  18. Lewis MM, Huang X, Nichols DE, Mailman RB. D1 and functionally selective dopamine agonists as neuroprotective agents in Parkinson's disease. CNS Neurol Disord Drug Targets. 2006; 5:345-53. [PMID: 16787233]
  19. Ogilvie JM, Hakenewerth AM, Gardner RR, Martak JG, Maggio VM. Dopamine receptor loss of function is not protective of rd1 rod photoreceptors in vivo. Mol Vis. 2009; 15:2868-78. [PMID: 20038975]
  20. Kipnis J, Cardon M, Avidan H, Lewitus GM, Mordechay S, Rolls A, Shani Y, Schwartz M. Dopamine, through the extracellular signal-regulated kinase pathway, downregulates CD4+CD25+ regulatory T-cell activity: implications for neurodegeneration. J Neurosci. 2004; 24:6133-43. [PMID: 15240805]
  21. Kashii S, Takahashi M, Mandai M, Shimizu H, Honda Y, Sasa M, Ujihara H, Tamura Y, Yokota T, Akaike A. Protective action of dopamine against glutamate neurotoxicity in the retina. Invest Ophthalmol Vis Sci. 1994; 35:685-95. [PMID: 7906683]
  22. Maher P, Hanneken A. The molecular basis of oxidative stress-induced cell death in an immortalized retinal ganglion cell line. Invest Ophthalmol Vis Sci. 2005; 46:749-57. [PMID: 15671309]
  23. Runchel C, Matsuzawa A, Ichijo H. Mitogen-activated protein kinases in mammalian oxidative stress responses. Antioxid Redox Signal. 2011; 15:205-18. [PMID: 21050144]
  24. Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene. 2004; 23:2838-49. [PMID: 15077147]
  25. Johnson GL, Dohlman HG, Graves LM. MAPK kinase kinases (MKKKs) as a target class for small-molecule inhibition to modulate signaling networks and gene expression. Curr Opin Chem Biol. 2005; 9:325-31. [PMID: 15939336]
  26. Cuevas BD, Abell AN, Johnson GL. Role of mitogen-activated protein kinase kinase kinases in signal integration. Oncogene. 2007; 26:3159-71. [PMID: 17496913]
  27. Fancellu R, Armentero MT, Nappi G, Blandini F. Neuroprotective effects mediated by dopamine receptor agonists against malonate-induced lesion in the rat striatum. Neurol Sci. 2003; 24:180-1. [PMID: 14598076]
  28. Yu Y, Wang JR, Sun PH, Guo Y, Zhang ZJ, Jin GZ, Zhen X. Neuroprotective effects of atypical D1 receptor agonist SKF83959 are mediated via D1 receptor-dependent inhibition of glycogen synthase kinase-3 beta and a receptor-independent anti-oxidative action. J Neurochem. 2008; 104:946-56. [PMID: 18005341]
  29. Zhang X, Zhou Z, Wang D, Li A, Yin Y, Gu X, Ding F, Zhen X, Zhou J. Activation of phosphatidylinositol-linked D1-like receptor modulates FGF-2 expression in astrocytes via IP3-dependent Ca2+ signaling. J Neurosci. 2009; 29:7766-75. [PMID: 19535588]
  30. Scheller D, Chan P, Li Q, Wu T, Zhang R, Guan L, Ravenscroft P, Guigoni C, Crossman AR, Hill M, Bezard E. Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease. Exp Neurol. 2007; 203:415-22. [PMID: 17045989]
  31. Panchalingam S, Undie AS. SKF83959 exhibits biochemical agonism by stimulating [(35)S]GTP gamma S binding and phosphoinositide hydrolysis in rat and monkey brain. Neuropharmacology. 2001; 40:826-37. [PMID: 11369036]
  32. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65:55-63. [PMID: 6606682]
  33. Lönnerdal B, Woodhouse LR, Glazier C. Compartmentalization and quantitation of protein in human milk. J Nutr. 1987; 117:1385-95. [PMID: 3498019]
  34. Wood JP, Osborne NN. Induction of apoptosis in cultured human retinal pigmented epithelial cells: the effect of protein kinase C activation and inhibition. Neurochem Int. 1997; 31:261-73. [PMID: 9220459]
  35. Krishnamoorthy RR, Agarwal P, Prasanna G, Vopat K, Lambert W, Sheedlo HJ, Pang IH, Shade D, Wordinger RJ, Yorio T, Clark AF, Agarwal N. Characterization of a transformed rat retinal ganglion cell line. Brain Res Mol Brain Res. 2001; 86:1-12. [PMID: 11165366]
  36. Van Bergen NJ, Wood JP, Chidlow G, Trounce IA, Casson RJ, Ju WK, Weinreb RN, Crowston JG. Recharacterization of the RGC-5 retinal ganglion cell line. Invest Ophthalmol Vis Sci. 2009; 50:4267-72. [PMID: 19443730]
  37. Ogata G, Stradleigh TW, Partida GJ, Ishida AT. Dopamine and background illumination activate D1 and D2-D5-type receptors in adult rat retinal ganglion cells. J Comp Neurol. 2012; xx:xx-xx.
  38. Rubinfeld H, Seger R. The ERK cascade: a prototype of MAPK signaling. Mol Biotechnol. 2005; 31:151-74. [PMID: 16170216]
  39. Widmann C, Gibson S, Jarpe MB, Johnson GL. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev. 1999; 79:143-80. [PMID: 9922370]
  40. Lin H, Chen C, Li X, Chen BD. Activation of the MEK/MAPK pathway is involved in bryostatin1-induced monocytic differenciation and up-regulation of X-linked inhibitor of apoptosis protein. Exp Cell Res. 2002; 272:192-8. [PMID: 11777344]
  41. Zhang X, Shan P, Otterbein LE, Alam J, Flavell RA, Davis RJ, Choi AM, Lee PJ. Carbon monoxide inhibition of apoptosis during ischemia-reperfusion lung injury is dependent on the p38 mitogen-activated protein kinase pathway and involves caspase 3. J Biol Chem. 2003; 278:1248-58. [PMID: 12399465]
  42. Okamoto S, Krainc D, Sherman K, Lipton SA. Antiapoptotic role of the p38 mitogen-activated protein kinase-myocyte enhancer factor 2 transcription factor pathway during neuronal differentiation. Proc Natl Acad Sci USA. 2000; 97:7561-6. [PMID: 10852968]
  43. Park JM, Greten FR, Li ZW, Karin M. Macrophage apoptosis by anthrax lethal factor through p38 MAP kinase inhibition. Science. 2002; 297:2048-51. [PMID: 12202685]
  44. Zarubin T, Han J. Activation and signaling of the p38 MAP kinase pathway. Cell Res. 2005; 15:11-8. [PMID: 15686620]